Filter

211 - 220 of 331 Results

  • The Last Major Phase of the COVID-19 Vaccination Roll-out: Children Under 5

    Issue Brief

    With the FDA authorization of both Moderna and Pfizer’s COVID-19 vaccine for children between the ages of 6 months and 5, the last major phase of the U.S. vaccination roll-out is underway. This brief provides an overview of the characteristics of children under the age of 5 and discusses some issues to consider in rolling out vaccination to this age group.

  • Diversity of Under-5 Age Group Varies Across States

    Feature

    Of the 19 million U.S. children under 5, half are children of color, making this group more diverse than the U.S. population overall. There is also significant variation across the country.

  • KFF COVID-19 Vaccine Monitor: October 2021

    Poll Finding

    This report tracks the public's COVID-19 vaccine intentions, including parents' intentions for their children ages 5-11 who may soon become eligible to get a vaccine. It also examines workers' experiences with and views toward employer vaccine mandates and the public's holiday plans heading into the second holiday season under the pandemic.

  • KFF COVID-19 Vaccine Monitor: Media and Misinformation

    Poll Finding

    This report examines COVID-19 misinformation and finds that nearly eight in ten adults either believe or are unsure about at least one false statement about COVID-19 or the vaccines. It also examines the news and social media sources the public trusts for information on the virus, and the relationship between news sources and belief in misinformation.

  • Monkeypox (MPX) Cases and Vaccinations by Race/Ethnicity

    Issue Brief

    A small number of states, as well as some local jurisdictions, are reporting race/ethnicity data on MPX cases and vaccinations and these data show a disproportionate impact of MPX cases on Black and Hispanic people. The data available to date on vaccinations also suggest that Black and Hispanic people are receiving smaller shares of vaccinations despite accounting for larger shares of cases.

  • Are There Enough COVID-19 Vaccines for America Without More Funding?

    Issue Brief

    This Data Note estimates how far the current U.S. supply of COVID-19 vaccines could stretch under different vaccination and booster scenarios. While estimated U.S. COVID-19 vaccine supply needs vary widely depending on assumptions and how many people choose to get vaccinated, this analysis indicates that under a plausible set of scenarios where 4th doses are recommended, the federal government is unlikely to have enough doses already purchased to cover the U.S. population.